Wave Life Sciences Surges to 6-Year High as Analysts Boost Targets Following Obesity Drug Data

Wave Life Sciences surged to a six-year high after the company reported encouraging clinical trial results for its obesity drug candidate WVE-007, igniting a wave of bullish analyst revisions. Cantor Fitzgerald raised its price target to $34 from $12, Citi to $30 from $16, and Wells Fargo to $29 from $16, while RBC upgraded the stock on strengthening confidence in the obesity asset. Analysts highlighted the drug's differentiated mechanism and promising early efficacy signals, positioning Wave as an emerging contender in one of the most competitive and high-growth therapeutic markets.

The upbeat sentiment fueled a spike in trading activity, including a notable surge in unusual call-option volume, as investors bet on continued upside. Analysts now project 57% to 76% potential gains from current levels, maintaining overweight and buy ratings across the board.